Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug
Autore:
Suwaki, T; Agrawal, DK; Townley, RG;
Indirizzi:
Creighton Univ, Sch Med, Dept Med, Omaha, NE 68178 USA Creighton Univ Omaha NE USA 68178 Sch Med, Dept Med, Omaha, NE 68178 USA Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Ctr Allergy Asthma & Immunol, Omaha, NE 68178 USA Creighton Univ Omaha NE USA 68178 y Asthma & Immunol, Omaha, NE 68178 USA
Titolo Testata:
INTERNATIONAL IMMUNOPHARMACOLOGY
fascicolo: 12, volume: 1, anno: 2001,
pagine: 2163 - 2171
SICI:
1567-5769(200111)1:12<2163:MOEFBS>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL-ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL-CELLS; PLATELET-ACTIVATING-FACTOR; COLONY-STIMULATING FACTOR; AIRWAY HYPERRESPONSIVENESS; SELECTIVE INDUCTION; GUINEA-PIGS; EXPRESSION; ASTHMA; CHEMOTAXIS;
Keywords:
asthma; eosinophil; IPD; suplatast tosilate; VCAM-1; VLA-4; anti-allergic drugs;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
52
Recensione:
Indirizzi per estratti:
Indirizzo: Agrawal, DK Creighton Univ, Sch Med, Dept Med, Criss 1 Room 131,2500 CalifPlaza, Omaha, NE 68178 USA Creighton Univ Criss 1 Room 131,2500 Calif Plaza Omaha NE USA 68178
Citazione:
T. Suwaki et al., "Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug", INT IMMUNO, 1(12), 2001, pp. 2163-2171

Abstract

Suplatast tosilate UPD), a new dimethylsulfonium agent, is used therapeutically in allergic diseases. Suplatast has been reported to attenuate airwayhyperresponsiveness in guinea pigs, human IgE synthesis, and murine peritoneal eosinophilia. However, the effect of suplatast on human eosinophils isnot known. In this study, we examined the effects of suplatast in human eosinophils on platelet activating factor (PAF, 1 muM)-induced chemotaxis by the blind well chamber technique, eosinophil adhesion to TNF-alpha (10 ng/ml) or IL-4 (10 ng/ml)-stimulated human umbilical vein endothelial cells (HUVECs), and expression of very late antigen-4 (VLA-4) on eosinophils and vascular cell adhesion molecule-1 (VCAM-1) on HUVECs by flow cytometry. Suplatast suppressed IL-4-induced eosinophil adhesion to HUVECs in a dose-dependent manner. Eosinophils from the normal subjects did not express VLA-4. However, there was a significant increase (P < 0.01) in the basal expression ofVLA-4 in allergic patients. PAF or IL-4 did not enhance VLA-4 expression on eosinophils, and there was no significant effect of suplatast on VLA-4 expression in allergic patients. Suplatast did not affect TNF-alpha -induced VCAM-1 expression. Interestingly, suplatast significantly suppressed IL-4 induced VCAM-1 expression on HUVECs and PAF-induced eosinophil chemotaxis. These data suggest that suplatast may modify eosinophil participation in airway inflammation by attenuating inflammatory mediators-induced chemotaxis and adhesion to endothelial cells, and thus might be useful in the treatmentof bronchial asthma. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 01:53:40